叶酸受体α 高表达与浆液性卵巢癌患者 生存率的相关性研究

Association of folate receptor α with survival rates in serous ovarian carcinoma

摘要:

目的 探讨浆液性卵巢癌患者叶酸受体α（FR-α）表达与卵巢癌患者生存率的相关性。方法 使 用实时荧光定量PCR 检测91 例浆液性卵巢癌患者肿瘤组织中FR-α 表达情况，以及分析患者其他临床病理参 数[ 如FIGO 分期、肿瘤分化程度、是否接受理想的手术、淋巴结转移、术前血清中肿瘤抗原125（CA125）含 量及FR-α 表达等与患者无病生存率（FDS）和总生存率（OS）的关系]。结果 FIGO 分期Ⅰ、Ⅱ、Ⅲ及Ⅳ期 的患者分别为4、6、65 及16 例，44% 患者接受最佳肿瘤细胞减灭术。晚期患者或是接受次理想减积手术患者 FR-α 表达较高。愈后分析表明，FR-α 高表达是FDS 较差的预后因子[H^R=2.70（1.20，6.05），P =0.016]，也 是OS 较短的预后因素[H^R=3.51（2.93，13.29），P =0.035]。结论 FR-α 高表达是浆液性卵巢癌患者FDS 和 OS 较差的预后因子，FR-α 是浆液性卵巢癌潜在的生物标志物和治疗靶点。

Abstract:

【Objective】 To investigate the correlation between expression of folate receptor α (FR- α) and prognosis in patients with serous ovarian carcinoma. Methods Expression of FR-α in tumor tissues was determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) for 91 patients with serous ovarian carcinoma. Relationship between clinicopathological parameters including FIGO stages, degree of tumor differentiation, acceptance of ideal operation, lymph node metastasis, preoperative serum CA-125 level and expression of FR-α and free disease survival (DFS) or overall survival (OS) was determined. Results There were 4, 6, 65, and 16 patients with FIGO stages Ⅰ, Ⅱ, Ⅲ, and Ⅳ ovarian carcinoma (I: 0.451; Ⅱ: 0.415; Ⅲ: 0.652; and Ⅳ: 0.768; P = 0.004), respectively. Forty-four percent of patients underwent optimal debulking. Expression of FR-α was higher in advanced patients or those who could not receive optimal debulking (received: 0.490; could not receive: 0.766, P = 0.003). Prognostic analysis suggested that high expression of FR-α represented poor outcome for both DFS [H^R = 2.70 (1.20, 6.05), P = 0.016] and OS [H^R = 3.51 (2.93, 13.29), P = 0.035]. Conclusion High expression of FR-α represents a risk factor in patients with serous ovarian carcinoma, which may be a potential biomarker and a therapeutic target.